This tool will take you through current, open clinical trials in the UK and help you to understand which trials may be suitable for you. With any clinical trial you will need to be referred by your Health Care Specialist, always seek advice when considering clinical trials.
Further information can be found on our website under Clincial Trials and Novel Drugs or if you would like to speak to someone please call the Myeloma UK infoline on: 0800 980 3332
The Myeloma Trial Finder is intended only to provide information about clinical trials currently available in the UK. Trials included on Myeloma Trial Finder are not necessarily endorsed by Myeloma UK. Clinical trials involve inherent risks and any decision to participate, or not participate, in a clinical trial should be taken only after a careful assessment of the risks involved in it. Please speak to your haematologist if you are interested in taking part in a clinical trial. To the fullest extent permitted by law Myeloma UK excludes all liability howsoever arising (including negligence) as a consequence of, or in connection with, the use of information provided by Myeloma Trial Finder
There are currently 27 open trials
Targeted radiotherapy for myeloma
Relapsed, Newly Diagnosed
The purpose of this study is to determine whether a radiolabelled antibody can be used to safely deliver radiotherapy to the bone marrow ahead of a stem cell transplant in patients who have high risk myeloma.
While stem cell transplants have been demonstrated to be effective treatments for myeloma, the results seen in patients with high risk disease is poor. Intensifying treatment prior to transplant has been shown to improve patient outcomes, and reduce the risk of relapse. Targeted radiotherapy may be an option for intensifying treatment and killing more myeloma cells prior to transplant without the side effects associated with standard treatments, for example high dose chemotherapy.
Royal Free Hospital, London;
University College Hospital, London;
Southampton General Hospital, Southampton
Who can enter the study?:
Patients with myeloma who are awaiting an autologous stem cell transplant. Patients must not be currently receiving chemotherapy, or have received chemotherapy within 3 weeks.
All patients will receive treatment with yttrium-90 anti-CD66, a radiolabelled antibody that will deliver radiotherapy directly to myeloma cells within the bone marrow.
Patients will be required to attend outpatient clinics for regular check-ups.
(for Medical Professionals):
This open label, single group assignment study aims to determine whether a radiolabelled antibody that targets the bone marrow can be administered safely to patients as part of preparatory treatment prior to an autologous stem cell transplant.
For more information, click here